Skip to main content

Advertisement

Table 1 Summary of results of recent series on fractionated radiotherapy for GH-secreting pituitary adenoma

From: Radiation techniques for acromegaly

Authors type of patients total dose follow-up tumor control biochemical remission    late toxicity (%)
  RT   (Gy) median (months) % % visual hypopituitarism
Barkan et al., 1997 [8] CRT 38 46 80 NA 5 NA NA
Thalassinos et al., 1998 [9] CRT 46 45-50 86 100 25 and 21 at 5 and 10 years 0 30 at 10 years
Barrande et al., 2000 [10] CRT 128 52 137 NA 35 and 53 at 5 and 10 years 3 50 at 10 years
Biermasz et al., 2000 [11] CRT 36 40 130 NA 40 and 61 at 5 and 10 years 0 29 and 54 at 5 and 10 years
Cozzi et al., 2001 [12] CRT 49 45 168 96 10 at 10 years 4 12
Epaminonda et al., 2001 [13] CRT 67 40-75 120 NA 65 at 15 years 0 NA
Jenkins et al., 2006 [15] CRT 656 45 84 NA 36 and 64 at 5 and 10 years 0 58 at 10 years°
       74 at 15 years   
Minniti et al., 2005 [14] CRT 45 45 144 95 29 and 52 at 5 and 10 years 0 45 at 10 years
       77 at 15 years   
Milker-Zabel et al.,2004 [26] FSRT 20 52.2 61 100 55 5 15
Colin et al., 2005 [27] FSRT 31* 50.4 80 99 20 and 50 at 5 and 10 years 0 37
Minniti et al., 2006 [28] FSRT 18* 45 39 98 50 at 5 years* 0 22
Roug et al., 2010 [29] FSRT 34 54 45 91 30 NA 29
  1. CRT, conventional radiotherapy; FSRT, fractionated stereotactic radiotherapy.
  2. *acromegalic patients included in series of FSRT for either secreting or non secreting pituitary tumors.
  3. °hypogonadism 58%, hypothyroidism 27%, and hyposurrenalism 15%, respectively.